C2N Diagnostics, a leader in precision neurology diagnostics, announced today a strategic partnership with Codex Genetics to introduce its groundbreaking PrecivityAD2 blood test in Hong Kong. The collaboration aims to enhance early detection of Alzheimer’s disease, providing clinicians with a non-invasive, scalable tool to assess patients presenting with cognitive concerns.

PrecivityAD2 evaluates biomarkers associated with amyloid pathology, the hallmark of Alzheimer’s disease, by analyzing amyloid beta peptide ratios in plasma, combined with patient-specific information, to generate a personalized risk score. Validated in multiple clinical studies, the test demonstrates high concordance with established imaging biomarkers, offering a practical alternative to more invasive or costly procedures such as PET scans or cerebrospinal fluid analysis.

Under the agreement, C2N Diagnostics will supply its proprietary PrecivityAD2 assay technology, including the analytical platform and biomarker interpretation framework. Codex Genetics will oversee regulatory compliance, local distribution, and patient access across Hong Kong, ensuring the test is available to hospitals, specialty clinics, and research centers throughout the region.

“This partnership represents a major milestone in bringing precision neurology tools to Asia,” said a spokesperson for C2N Diagnostics. “By combining our advanced blood test technology with Codex Genetics’ deep regional expertise, we can support clinicians in identifying at-risk individuals earlier, guide personalized care, and facilitate participation in clinical trials.”

The collaboration is designed not only to broaden access to cutting-edge diagnostics but also to build local expertise in Alzheimer’s biomarker interpretation and integration into clinical workflows. Through this initiative, both companies aim to enable early intervention strategies, improve patient outcomes, and advance research in neurodegenerative disease management.

C2N Diagnostics emphasizes that PrecivityAD2 is part of a broader commitment to precision medicine, empowering clinicians to deliver more informed and timely care. Codex Genetics’ involvement ensures that patients in Hong Kong have streamlined access to testing, comprehensive support services, and reliable delivery of results.

“Together, we are taking a significant step toward transforming Alzheimer’s care in Hong Kong,” the spokesperson added. “Early detection is crucial, and with PrecivityAD2, clinicians now have a practical and validated tool to make informed decisions that can improve patient outcomes.”